ArticleClinical rheumatology2013
Rituximab-induced regression of CREST-related calcinosis.
Article in Clinical rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 47 citations in OpenAlex.
- Calcinosis Cutis Universalis: A Review of Therapeutic Strategies and Surgical Management.Journal of clinical medicine · 2026Review
- Ectopic calcifications in the musculoskeletal field: the basis for preventive and curative pharmacological strategies.Clinical rheumatology · 2025Review
- Treatment of calcinosis cutis associated with autoimmune connective tissue diseases.Archives of dermatological research · 2024Review
- Calcinosis Prevalence in Autoimmune Connective Tissue Diseases-A Retrospective Study.Journal of clinical medicine · 2024Article
- Systemic Sodium Thiosulfate as an Adjunct Treatment in Calcinosis: A Retrospective Study.Journal of clinical medicine · 2023Article
- Review
- Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.American journal of clinical dermatology · 2023Review
- Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?Journal of scleroderma and related disorders · 2022Review
- Late-onset calcinosis in burn scars: A review of the literature and two case reports.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2022Review
- Is biological therapy in systemic sclerosis the answer?Rheumatology international · 2020Review
- Is rituximab an effective treatment of refractory calcinosis?BMJ case reports · 2016Article
- Systemic sclerosis: commonly asked questions by rheumatologists.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2015Review
- The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.Current rheumatology reports · 2014Review
- Epidemiology and Treatment of Calcinosis Cutis: 13 Years of Experience.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About a quarter of sclerodermic patients present calcinosis. However, patients with limited form of the disease are more likely to have calcinosis than patients with diffuse form. We report a case of a 54-year-old female patient with limited cutaneous scleroderma using rituximab (RTX) to treat lung fibrosis and arthritis. Into RTX treatment, she also had a complete resolution of calcinosis in her hands. The patient reported improvement in dyspnea and synovitis after two courses of RTX (four weekly infusions 375 mg/m(2) each). After 7 months of the first infusion, the calcinosis in her fingers had a complete remission, especially the right thumb. Based on current evidences, we discuss the use of rituximab as a promising therapy to treat not only lung disease but also calcinosis in patients with scleroderma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.